Your browser is no longer supported. Please, upgrade your browser.
CRL Charles River Laboratories International, Inc. monthly Stock Chart
CRL [NYSE]
Charles River Laboratories International, Inc.
Index- P/E39.90 EPS (ttm)5.43 Insider Own1.50% Shs Outstand49.55M Perf Week-1.29%
Market Cap10.70B Forward P/E25.70 EPS next Y8.43 Insider Trans-11.35% Shs Float48.93M Perf Month-0.84%
Income271.40M PEG3.53 EPS next Q1.79 Inst Own96.60% Short Float1.27% Perf Quarter27.53%
Sales2.75B P/S3.89 EPS this Y13.30% Inst Trans-0.23% Short Ratio1.79 Perf Half Y71.73%
Book/sh35.37 P/B6.13 EPS next Y16.16% ROA5.50% Target Price238.00 Perf Year60.30%
Cash/sh8.16 P/C26.55 EPS next 5Y11.31% ROE16.50% 52W Range95.58 - 228.86 Perf YTD41.90%
Dividend- P/FCF25.72 EPS past 5Y13.40% ROI8.50% 52W High-5.28% Beta1.15
Dividend %- Quick Ratio1.50 Sales past 5Y15.10% Gross Margin36.10% 52W Low126.79% ATR6.27
Employees17100 Current Ratio1.70 Sales Q/Q3.80% Oper. Margin13.60% RSI (14)53.26 Volatility3.29% 3.01%
OptionableYes Debt/Eq1.29 EPS Q/Q52.40% Profit Margin9.90% Rel Volume0.52 Prev Close211.83
ShortableYes LT Debt/Eq1.26 EarningsAug 05 BMO Payout0.00% Avg Volume346.81K Price216.77
Recom1.70 SMA200.54% SMA502.60% SMA20027.56% Volume180,065 Change2.33%
Sep-10-20Upgrade Jefferies Hold → Buy $254
Jul-01-20Upgrade BofA Securities Neutral → Buy $192
May-13-20Upgrade UBS Neutral → Buy $177 → $200
Apr-21-20Downgrade Jefferies Buy → Hold $139
Mar-27-20Upgrade Morgan Stanley Equal-Weight → Overweight $152
Mar-02-20Initiated Deutsche Bank Buy $190
Feb-18-20Upgrade Wolfe Research Peer Perform → Outperform
Jan-10-20Upgrade Goldman Neutral → Buy $143 → $179
Jan-08-20Initiated Wells Fargo Overweight $180
Jan-07-20Initiated Citigroup Buy $185
Oct-18-19Downgrade BofA/Merrill Buy → Neutral $150
Jun-10-19Initiated SVB Leerink Outperform $155
Apr-30-19Resumed Evercore ISI Outperform $160
Dec-14-18Initiated Deutsche Bank Buy
Oct-09-18Initiated UBS Neutral
Aug-23-18Upgrade Raymond James Mkt Perform → Outperform
Jul-17-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Jun-15-18Upgrade KeyBanc Capital Mkts Sector Weight → Overweight
Feb-14-18Upgrade SunTrust Hold → Buy
Jan-22-18Downgrade SunTrust Buy → Hold
Sep-26-20 09:51AM  
Sep-23-20 11:49AM  
Sep-21-20 02:52PM  
Sep-15-20 04:03PM  
03:11PM  
02:25PM  
11:36AM  
Sep-13-20 08:00PM  
08:00PM  
Sep-09-20 09:35AM  
Sep-08-20 08:30AM  
Aug-31-20 08:59AM  
Aug-28-20 11:20AM  
Aug-24-20 02:08PM  
Aug-07-20 02:00AM  
Aug-05-20 05:00PM  
09:05AM  
07:53AM  
07:21AM  
07:00AM  
Aug-04-20 05:53PM  
05:39PM  
09:41AM  
09:07AM  
Jul-31-20 12:32PM  
Jul-29-20 12:33PM  
Jul-24-20 07:39PM  
Jul-22-20 09:19AM  
Jul-20-20 12:10PM  
Jul-15-20 04:42PM  
Jul-14-20 08:30AM  
Jul-13-20 05:03PM  
Jul-09-20 03:24PM  
Jun-15-20 09:59AM  
Jun-11-20 10:05AM  
09:02AM  
Jun-10-20 10:25AM  
Jun-03-20 02:46AM  
Jun-02-20 08:00AM  
07:58AM  
Jun-01-20 08:00AM  
May-30-20 10:54PM  
11:42AM  
May-28-20 11:00AM  
May-21-20 07:13AM  
May-09-20 09:12AM  
May-08-20 12:31AM  
May-07-20 08:25AM  
07:00AM  
Apr-30-20 12:34PM  
Apr-29-20 12:08PM  
Apr-20-20 03:24PM  
Apr-19-20 03:54PM  
Apr-16-20 08:40AM  
08:30AM  
Mar-30-20 08:30AM  
Mar-25-20 06:26AM  
Mar-22-20 10:56PM  
Mar-10-20 08:30AM  
Mar-04-20 08:00AM  
Feb-14-20 09:31AM  
Feb-13-20 07:11AM  
06:37AM  
Feb-12-20 12:00PM  
10:30AM  
09:15AM  
Feb-11-20 09:19AM  
08:25AM  
07:00AM  
Feb-06-20 09:18AM  
Feb-05-20 08:44AM  
Feb-04-20 12:30PM  
Jan-22-20 07:46AM  
Jan-21-20 04:30PM  
09:11AM  
Jan-19-20 08:16AM  
Jan-17-20 03:34PM  
09:15AM  
Jan-16-20 08:00AM  
Jan-15-20 12:10PM  
Jan-13-20 08:30AM  
08:00AM  
Jan-08-20 09:15AM  
Jan-07-20 11:50AM  
Jan-03-20 08:30AM  
Dec-26-19 10:56AM  
Dec-24-19 06:44AM  
Dec-18-19 07:35PM  
Dec-16-19 02:33PM  
07:00AM  
Dec-10-19 08:00AM  
07:51AM  
Dec-09-19 04:30PM  
Dec-04-19 04:30PM  
Dec-03-19 10:02AM  
Nov-28-19 05:40AM  
Nov-12-19 04:36AM  
Nov-11-19 08:30AM  
Nov-06-19 08:35AM  
07:00AM  
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as bioanalysis, drug metabolism, pharmacokinetics, safety pharmacology, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MASSARO GEORGEDirectorSep 14Sale219.911,943427,2849,441Sep 15 05:47 PM
Girshick BirgitCorporate Executive VPAug 20Sale213.51933199,20522,852Aug 21 10:48 AM
CHUBB STEPHEN DDirectorAug 18Sale217.651,000217,65137,657Aug 19 02:48 PM
Knell Michael GunnarCSVP&Chief Accounting OfficerAug 07Option Exercise111.413,441383,3535,855Aug 10 03:20 PM
Smith David RossCorporate Executive VP & CFOAug 07Option Exercise144.673,304477,99024,071Aug 10 04:18 PM
Kochevar Deborah TurnerDirectorAug 07Sale216.242,319501,4676,728Aug 11 10:39 AM
FOSTER JAMES CChairman, President and CEOAug 07Sale217.4924,0005,219,771210,777Aug 10 04:25 PM
Knell Michael GunnarCSVP&Chief Accounting OfficerAug 07Sale216.603,456748,5552,399Aug 10 03:20 PM
Smith David RossCorporate Executive VP & CFOAug 07Sale216.543,304715,44420,767Aug 10 04:18 PM
MASSARO GEORGEDirectorMay 22Sale173.40941163,16811,884May 26 02:37 PM
BERTOLINI ROBERT JDirectorMay 20Option Exercise52.293,530184,58432,664May 21 11:36 AM
BERTOLINI ROBERT JDirectorMay 20Sale174.583,530616,26329,134May 21 11:36 AM
LaPlume Joseph WEVP, Corp Strategy & DevelopMay 18Sale174.6535061,1289,637May 19 04:18 PM
FOSTER JAMES CChairman, President and CEOMay 18Sale175.0017,4353,051,125229,894May 19 04:14 PM
LaPlume Joseph WEVP, Corp Strategy & DevelopMay 15Option Exercise80.486,350511,04525,405May 19 04:18 PM
LaPlume Joseph WEVP, Corp Strategy & DevelopMay 15Sale168.2615,4182,594,1709,987May 19 04:18 PM
Girshick BirgitCorporate Executive VPMay 12Sale165.74780129,27721,837May 13 08:18 AM
FOSTER JAMES CChairman, President and CEOMay 11Sale162.5317,4462,835,433249,329May 13 11:02 AM
Smith David RossCorporate Executive VP & CFOMay 07Sale150.001,884282,60018,591May 08 10:48 AM
Barbo William DCorporate Executive VP & CCOMar 05Option Exercise102.5612,4671,278,67730,201Mar 06 03:50 PM
Barbo William DCorporate Executive VP & CCOMar 05Sale164.3513,9662,295,30016,235Mar 06 03:50 PM
CHUBB STEPHEN DDirectorFeb 27Option Exercise55.177,170395,57242,005Feb 28 10:28 AM
CHUBB STEPHEN DDirectorFeb 27Sale160.892,464396,43739,541Feb 28 10:28 AM
FOSTER JAMES CChairman, President and CEOFeb 26Option Exercise73.7025,1241,851,639311,899Feb 27 02:45 PM
Smith David RossCorporate Executive VP & CFOFeb 26Option Exercise73.704,188308,65624,663Feb 27 02:48 PM
FOSTER JAMES CChairman, President and CEOFeb 26Sale162.2525,1244,076,411286,775Feb 27 02:45 PM
Smith David RossCorporate Executive VP & CFOFeb 26Sale162.264,188679,53520,475Feb 27 02:48 PM
Smith David RossCorporate Executive VP & CFOFeb 24Option Exercise98.028,211804,86029,065Feb 25 11:29 AM
FOSTER JAMES CChairman, President and CEOFeb 24Option Exercise97.8044,3034,332,960333,349Feb 26 10:15 AM
FOSTER JAMES CChairman, President and CEOFeb 24Sale167.833,000503,490750Feb 26 10:15 AM
FOSTER JAMES CChairman, President and CEOFeb 24Sale166.7044,3037,385,433289,046Feb 26 10:15 AM
Smith David RossCorporate Executive VP & CFOFeb 24Sale166.728,2111,368,95320,854Feb 25 11:29 AM
MILNE GEORGE M JRDirectorFeb 18Option Exercise55.177,170395,57234,207Feb 19 10:41 AM
MILNE GEORGE M JRDirectorFeb 18Sale176.077,1701,262,43027,037Feb 19 10:41 AM
WALLMAN RICHARD FDirectorFeb 14Option Exercise52.293,530184,58432,897Feb 14 05:10 PM
WALLMAN RICHARD FDirectorFeb 14Sale174.293,530615,25829,367Feb 14 05:10 PM
BERTOLINI ROBERT JDirectorFeb 13Option Exercise55.177,170395,57235,045Feb 14 12:24 PM
WALLMAN RICHARD FDirectorFeb 13Option Exercise55.177,170395,57236,537Feb 14 05:07 PM
FOSTER JAMES CChairman, President and CEOFeb 13Sale171.9015,0002,578,440298,064Feb 14 03:06 PM
Girshick BirgitCorporate Executive VPFeb 13Sale172.05900154,84523,714Feb 14 09:43 AM
Smith David RossCorporate Executive VP & CFOFeb 13Sale170.294,500766,31921,978Feb 13 07:08 PM
WALLMAN RICHARD FDirectorFeb 13Sale172.027,1701,233,39129,367Feb 14 05:07 PM
BERTOLINI ROBERT JDirectorFeb 13Sale170.417,1701,221,81927,875Feb 14 12:24 PM
Barbo William DCorporate Executive VP & CCOFeb 13Sale172.116,9011,187,69918,931Feb 14 12:01 PM
JOHST DAVID PCorporate Executive VPDec 09Option Exercise76.6724,6601,890,682237,514Dec 11 10:36 AM
JOHST DAVID PCorporate Executive VPDec 09Sale144.2124,6603,556,341212,854Dec 11 10:36 AM
Girshick BirgitCorporate Executive VPDec 09Sale145.551,051152,97217,715Dec 10 05:00 PM
Girshick BirgitCorporate Executive VPDec 09Sale144.932,874416,51618,766Dec 10 04:58 PM
Girshick BirgitCorporate Executive VPDec 09Sale144.212,420348,99321,640Dec 10 04:55 PM
Girshick BirgitCorporate Executive VPNov 13Option Exercise91.199,604875,77833,664Nov 14 05:21 PM
Girshick BirgitCorporate Executive VPNov 13Sale137.231,499205,71224,060Nov 14 05:23 PM
Girshick BirgitCorporate Executive VPNov 13Sale137.048,1051,110,71725,559Nov 14 05:21 PM